Venn Therapeutics is an integrin therapeutics precision medicine company. We are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of cancer, fibrosis and NASH.



TGF-β activation has the potential to significantly expand the universe of cancers that can be successfully and safely targeted with IO therapy, as well as increasing the efficacy and potency of existing therapies.


Our lead asset, VTX-001, is a monoclonal antibody that selectively targets integrin αvβ8 and has shown single-agent activity in multiple preclinical cancer models. VTX-001 has been shown to safely target TGF-β1 and TGF-β3 and completely avoid blocking TGF-β2. The blockage of TGF-β2 is associated with cardiac toxicity, a harmful complication of many existing cancer therapies. In addition to VTX-001, Venn’s integrin portfolio includes two other first-in-class monoclonal antibodies under development targeting integrins, as well as a proprietary companion diagnostic, VTX-001DX, which measures human αvβ8 expression. We have a proven track record of acquiring and efficiently advancing promising, cutting edge early-stage assets. Current preclinical integrin oncology assets in our portfolio have the potential for significant future partnerships. To learn more about our science, visit us here


Our Scientific Advisory Board is led by internationally-renowned scientific leaders.  Our goal is to become the preeminent oncology franchise for pharmaceutical companies seeking the most promising advances in immuno-oncology, and an industry leader in therapeutics translations from preclinical to Phase 1/2 studies. Venn has multiple important milestones in the near future, including a first-in-human (FIH) clinical trial.